Efficacy and Safety of Jinhua Qinggan Granules (JHQG) for the Use of Acute Upper Respiratory Infection

The goal of this clinical trial is to learn if drug Jinhua Qinggan Granules (JHQG) works to treat acute upper respiratory tract infection in adults. It will also learn about the safety of drug JHQG. The main questions it aims to answer is: • Following three days of treatment, the overall grade of fever, sore throat, nasal congestion, rhinorrhea, headache, sneezing, cough, and malaise dropped to zero for a whole day. Researchers will compare drug JHQG to a placebo (a look-alike substance that contains no drug) to see if drug JHQG works to treat acute upper respiratory tract infection. Participants will: * Take drug JHQG or a placebo 3 times daily for 3 days * All subjects are followed up before the trial, and on the same day or day after completing 3 days of medication.

Inclusion Criteria: 1. Diagnosed with AURI; 2. Wind-heat of TCM pattern differentiation; 3. 18 ≤Age ≤ 65; 4. At screening, axillary temperature ≥37.3 ºC and ≤39.0 ºC; 5. At randomization and group assignment, disease course within 48 hours; 6. The subject has signed the informed consent form. Exclusion Criteria: 1. Patients with influenza, COVID-19, suppurative otitis media, suppurative tonsillitis, acute attack of asthma and chronic obstructive pulmonary disease, pulmonary tuberculosis, primary ciliary dyskinesia syndrome, pleural effusion, interstitial lesions, acute and chronic tracheobronchitis, lower respiratory infections such as pneumonia; 2. WBC \> 11.0×109 or NEU% \> 80% or with symptoms of thick sputum and suspected bacterial infection; 3. ALT, AST \> 2 ULN or CRE\>ULN; 4. Nasal surgery, nasopharyngeal radiotherapy, acute and chronic nasal diseases or abnormal nasal mucosal function (e.g. rhinitis, sinusitis); 5. Patients with diseases diagnosed by specific pathogens (e.g. mumps, measles, hemorrhagic fever, typhoid, chicken pox, allergic rhinitis); 6. Fever caused by other clearly diagnosed organic diseases outside the respiratory system; 7. Accompanied by cardiovascular diseases (e.g. coronary heart disease, myocarditis, etc., excluding hypertension with stable blood pressure control and asymptomatic old lacunar infarction), major kidney, liver, hematological diseases, major nervous and neuromuscular diseases, major metabolic and endocrine diseases and immunosuppression (including immunosuppressant or HIV infection, etc.), and malignant tumor; 8. Subjects, who were treated with antivirals, antibiotics, western or traditional medicines for alleviating symptoms of upper respiratory infection within 12 hours before enrollment; 9. Allergic individuals and those who are known to be allergic to investigational drugs, including the ingredients of this product, acetaminophen or drug excipients; 10. Women who are pregnant or plan to become pregnant within the next 1 months, lactating women; from signature of informed consent form, until 30 days after the last study medication, patients of childbearing age who are unable or unwilling to use adequate contraception or their spouses are unwilling to use contraception; 11. Suspected or do have a history of alcohol or drug abuse; 12. Participated in other clinical trials or are participating in other clinical trials in the past 3 months; 13. Subjects not suitable for enrollment based on investigators' judgment.